Considering metformin in cardiometabolic protection in psychosis.
Early Psychosis Programme, Eastern Suburbs Mental Health Programme, Sydney, Australia. j.curtis@unsw.edu.au
J
J
Curtis
H
H
Newall
N
N
Myles
D
D
Shiers
K
K
Samaras
D014150:Antipsychotic Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008687:Metformin / Q000627:therapeutic use*; D009765:Obesity / Q000517:prevention & control; D011618:Psychotic Disorders / Q000150:complications*; D015430:Weight Gain
D014150:Antipsychotic Agents; D007004:Hypoglycemic Agents; D008687:Metformin